Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Saved in:
Bibliographic Details
Title: Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.
Authors: Siebenhaar F; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany., Broesby-Olsen S; Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark., Castells M; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., George TI; ARUP Laboratories and Huntsman Cancer Institute, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah., Livideanu CB; Department de dermatologie, Expert Centre of Mastocytosis (CEREMAST) CHU de Toulouse, Toulouse University Hospital - Larrey Hospital, Toulouse, France., Álvarez-Twose I; Institute of Mastocytosis Studies of Castilla-La Mancha, Virgen del Valle Hospital, Toledo, Spain., Panse J; Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital Aachen, Medical Faculty, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany., Barete S; Unit of Dermatology, Reference Centre for Mastocytosis (CEREMAST) Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France., Reiter A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Dybedal I; Departments of Hematology and Pharmacology, Oslo University Hospital, Oslo, Norway., Akin C; Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Michigan., Van Daele P; Department of Internal Medicine and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands., Radia DH; Guy's & St Thomas' NHS Foundation Trust, London, UK., Cerquozzi S; Department of Medicine, University of Calgary, Calgary, Alberta, Canada., Ustun C; Section of Bone Marrow Transplantation and Cellular Therapy, Division of Hematology, Oncology and Cell Therapy, Department of Internal Medicine, Rush Medical College, Chicago, Illinois., Sabato V; Department of Immunology, Allergology, and Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium., Gotlib J; Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California., Rafferty M; The Beatson West of Scotland Cancer Centre, Glasgow, Scotland., DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schafhausen P; Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Ungerstedt J; Department of Medicine, Karolinska Institutet, Huddinge, Sweden., Ogbogu PU; Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital; Case Western Reserve University School of Medicine, Cleveland, Ohio., Florell S; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah., Wada DA; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah., Rets A; ARUP Laboratories and Huntsman Cancer Institute, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah., Lin HM; Blueprint Medicines Corporation, Cambridge, Massachusetts., Bidollari I; Blueprint Medicines Corporation, Cambridge, Massachusetts., Hong J; Blueprint Medicines Corporation, Cambridge, Massachusetts., Shaheen D; Blueprint Medicines Corporation, Cambridge, Massachusetts., Lampson B; Blueprint Medicines Corporation, Cambridge, Massachusetts., Hartmann K; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: karin.hartmann@usb.ch.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2026 Jun; Vol. 94 (6), pp. 1705-1713. Date of Electronic Publication: 2026 Feb 12.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-6787
DOI:10.1016/j.jaad.2026.02.025